3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
15
Nivolumab
9
atezolizumab
5
Ipilimumab
4
Drug Therapy
4
Docetaxel
4
Radiotherapy
3
Radiosurgery
3
Paclitaxel
3
Gemcitabine
3
Cetuximab
3
Carboplatin
3
Blood Specimen Collection
3
temsirolimus
2
spartalizumab
2
sargramostim
2
motexafin gadolinium
2
liposomal doxorubicin
2
entinostat
2
durvalumab
2
belinostat
2
Sirolimus
2
Psychiatric Rehabilitation
2
Peripheral Blood Stem Cell Transplantation
2
Metformin
2
Irinotecan
2
Fluorouracil
2
Etoposide
2
Dexamethasone
2
Cyclophosphamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Blood Component Removal
×
Thoracic
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled